It was October 2007 when Ann Havelock, who was 67-years-old at the time, started feeling that something was wrong…
Articles by Patrícia Silva, PhD
Therapeutic plasma exchange (TPE) is a novel method for patients with scleroderma that may revolutionize the treatment of the…
The Scleroderma Foundation has made an appeal for scleroderma patients to participate in a research study focused on assessing …
Cumberland Pharmaceuticals, Inc., recently announced the addition to its drug pipeline of Vasculan (ifetroban), an oral capsule that soon will enter clinical…
The Phase 3 STAR clinical trial from Cytori Therapeutics recently enrolled and treated its 60th patient — 75 percent of target patient…
The U.S. Food and Drug Administration (FDA) has designated a potential gene therapy for localized scleroderma, FCX-013 by Fibrocell Science,…
The U.S. Food and Drug Administration (FDA) approved Corbus Pharmaceuticals’ 12-month, open-label extension study of its ongoing Phase 2 clinical…
Cytori Therapeutics has enrolled and treated its 40th patient with scleroderma in the Phase 3 STAR clinical trial for ECCS-50, marking 50…
In July 2014, Edward Harris launched a website called the Scleroderma Education Project, where he writes and publishes articles…
Canada-based ProMetic Life Sciences, a global biopharma, recently announced it will launch a double-blind, placebo-controlled Phase 2 clinical trial in…